Última actualização :
18/04/2024
Antiepiléptico   Fosphenytoin sodium  
Injetável
Estabilidade em soluções simples Estabilidade em misturas Factores que afectam a sua estabilidade Compatibilidade Método de administração Bibliografía Pdf
   Estrutura química  

Nomes comerciais nos diversos países   Nomes comerciais nos diversos países     

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Cerebryx Canadá, Estados Unidos de América
Fosphen Índia
Fostoin Japón
Pro - Epanutin Austria, Dinamarca, Finlandia, Gran-bretanha, Irlanda, Islandia, Luxemburgo, Noruega, Países Baixos, Suècia
Prodilantin Alemanha, Austria, Bélgica, Dinamarca, Estados Unidos de América, Finlandia, França, Gran-bretanha, Grècia, Hungria, Irlanda, Islandia, Itália, Japón, Luxemburgo, Países Baixos, Polonia, Suècia, Suicia
Bibliografía   Injetável   Bibliografía : Fosphenytoin sodium  
Tipo Publicação
800 Jornal Fischer JH, Cwik MJ, Luer MS, Sibley CB, Deyo KL.
Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes.
Ann Pharmacotherapy 1997 ; 31: 553-559.
1412 Jornal Brett A, Riggs RM, Webster AA, Benner KW.
Y-site stability of fosphenytoin and sodium phenobarbital.
Int J Pharm Compound 1999 ; 3: 64-66.
1419 Jornal Riggs RM, English BA, Webster AA, McGuire JM, Riordan JM.
Fosphenytoin Y-site stability studies with lorazepam and midazolam hydrochloride.
Int J Pharm Compound 1999 ; 3: 235-238.
1803 Jornal Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
3379 Jornal Fox L.M, Wilder A.G, Foushee J.A.
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Am J Health-Syst Pharm 2013 ;70:520-524.
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3967 Jornal Staven V, Herra I, Wang S, Grönlie I,Tho I.
Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents.
J Pharm Pharmacol 2017 ;69,7:448-462
4145 Jornal Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4370 Jornal Staven V, Wang S, Gronlie I, Tho I.
Physical stability of an all-in one parenteral nutrition admixture for preterm infants upon mixing with micronutrients and drugs
EJHP 2018 2018;0:1-7
4428 Jornal Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J.
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma.
J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4433 Jornal Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4569 Jornal Lee T.M , Villareal C.L, Meyer L.M.
Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.
Hosp Pharm 2021 ; 56, 4: 282-286.

  Mentions Légales